Rhumbline Advisers lifted its stake in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 1.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 260,795 shares of the biotechnology company’s stock after acquiring an additional 3,467 shares during the quarter. Rhumbline Advisers owned approximately 0.30% of Progenics Pharmaceuticals worth $1,318,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Bank of New York Mellon Corp increased its position in Progenics Pharmaceuticals by 0.7% during the second quarter. Bank of New York Mellon Corp now owns 1,171,273 shares of the biotechnology company’s stock worth $7,226,000 after buying an additional 7,574 shares during the last quarter. TD Asset Management Inc. acquired a new stake in shares of Progenics Pharmaceuticals in the second quarter valued at about $262,000. DekaBank Deutsche Girozentrale grew its position in shares of Progenics Pharmaceuticals by 62.3% in the second quarter. DekaBank Deutsche Girozentrale now owns 43,000 shares of the biotechnology company’s stock valued at $250,000 after purchasing an additional 16,500 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Progenics Pharmaceuticals by 7.2% in the second quarter. Vanguard Group Inc. now owns 5,463,704 shares of the biotechnology company’s stock valued at $33,712,000 after purchasing an additional 364,803 shares during the last quarter. Finally, State of Alaska Department of Revenue grew its position in shares of Progenics Pharmaceuticals by 129.6% in the third quarter. State of Alaska Department of Revenue now owns 66,377 shares of the biotechnology company’s stock valued at $335,000 after purchasing an additional 37,470 shares during the last quarter. 76.94% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:PGNX opened at $5.76 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.76 and a current ratio of 3.76. The company has a market cap of $505.57 million, a P/E ratio of -9.14 and a beta of 2.82. The stock’s 50-day moving average is $5.34 and its 200-day moving average is $4.99. Progenics Pharmaceuticals, Inc. has a 52-week low of $3.42 and a 52-week high of $6.31.
Several brokerages have recently issued reports on PGNX. BidaskClub raised Progenics Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, November 8th. Brookline Capital Management began coverage on Progenics Pharmaceuticals in a research report on Monday, July 29th. They issued a “buy” rating and a $10.00 price target on the stock. Zacks Investment Research downgraded Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 3rd. ValuEngine downgraded Progenics Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 15th. Finally, BTIG Research set a $14.00 price target on Progenics Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, August 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Progenics Pharmaceuticals has a consensus rating of “Buy” and an average target price of $8.94.
In related news, insider Velan Capital, L.P. purchased 277,424 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was acquired at an average price of $4.39 per share, with a total value of $1,217,891.36. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Lte Partners, Llc purchased 43,520 shares of the stock in a transaction that occurred on Thursday, September 5th. The stock was bought at an average cost of $4.62 per share, with a total value of $201,062.40. The disclosure for this purchase can be found here. In the last three months, insiders purchased 677,306 shares of company stock valued at $2,968,406. 4.26% of the stock is currently owned by company insiders.
Progenics Pharmaceuticals Profile
Progenics Pharmaceuticals, Inc, an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer.
Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.